{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mao Y"],"funding":["Xianyang Science and Technology Planning Project"],"pagination":["e0332378"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12435719"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(9)"],"pubmed_abstract":["<h4>Background</h4>Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common and clinically significant complication of ERCP, with an incidence of 3.5-9.7% in general populations and up to 14.7% in high-risk groups, leading to considerable morbidity, mortality, and healthcare costs. Although numerous multivariable prediction models have been developed, their predictor sets, methodological rigor, and clinical applicability remain highly variable.<h4>Method</h4>We conducted a PRISMA 2020-compliant systematic review and meta-analysis, prospectively registered in PROSPERO (CRD42024556967). Nine databases were searched to June 1, 2024, for studies developing or validating multivariable PEP risk prediction models. Data on study/model characteristics, predictors, a"],"journal":["PloS one"],"pubmed_title":["Risk prediction model for post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis."],"pmcid":["PMC12435719"],"funding_grant_id":["L2023-ZDYF-SF-055"],"pubmed_authors":["Fan H","Ouyang X","Dong H","He W","Li E","Liu Q","Wang X","Zhang C","Mao Y","Qiu L"],"additional_accession":[]},"is_claimable":false,"name":"Risk prediction model for post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis.","description":"<h4>Background</h4>Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common and clinically significant complication of ERCP, with an incidence of 3.5-9.7% in general populations and up to 14.7% in high-risk groups, leading to considerable morbidity, mortality, and healthcare costs. Although numerous multivariable prediction models have been developed, their predictor sets, methodological rigor, and clinical applicability remain highly variable.<h4>Method</h4>We conducted a PRISMA 2020-compliant systematic review and meta-analysis, prospectively registered in PROSPERO (CRD42024556967). Nine databases were searched to June 1, 2024, for studies developing or validating multivariable PEP risk prediction models. Data on study/model characteristics, predictors, a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-01T14:06:31.11Z","creation":"2026-04-08T13:19:08.419Z"},"accession":"S-EPMC12435719","cross_references":{"pubmed":["40953036"],"doi":["10.1371/journal.pone.0332378"]}}